The failure led to Merck & Co Inc's Keytruda getting a leg up in the key immuno-oncology field and Bristol-Myers' becoming the target of activist investors.
U.S. health regulators on Wednesday placed a partial hold on three trials testing Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies on a rival drug.
Cowen and Co. analysts estimate Opdivo could generate sales of $12.36 billion in 2022, of which renal cell carcinoma would account for about $1.7 billion.
Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for more than 100,000 deaths worldwide each year, Bristol-Myers estimates.
This article was provided by Reuters.